Leidi.com Lei Jianping June 2
Yaoshibang Co., Ltd. (abbreviation: "Yaoshibang") recently updated its prospectus again, preparing to list in Hong Kong.
This is the third time that Pharmacist has submitted a prospectus after a year.
Annual revenue of 14.3 billion
According to reports, Yaoshibang is a digital comprehensive service platform for the out-of-hospital pharmaceutical industry, focusing on improving the efficiency of drug circulation in the out-of-hospital market, and is committed to providing abundant and accessible medicines and efficient and convenient digital tools for more than 1 million grassroots pharmacies, clinics, and clinics .
Yaoshibang's systematic SaaS tools cover pharmaceutical companies, pharmaceutical wholesale enterprises, as well as pharmaceutical retail and primary medical terminals such as pharmacies and clinics, and realize the product data, user data, capital flow data and logistics data of each main body through the online trading platform And so on the seamless link of the whole process.
Each subject was originally an isolated island of information. Through the pharmacist help platform to realize the connection, the supply and demand sides that have never intersected before can bridge the gap between regions and information, and the efficiency of drug distribution is improved.
According to the prospectus, Yaoshibang’s revenue in 2020, 2021, and 2022 will be 6.065 billion yuan, 10.09 billion yuan, and 14.275 billion yuan; gross profits will be 609 million yuan, 914 million yuan, and 1.435 billion yuan; %, 9.1%, 10.1%;
Yaoshibang’s losses in 2020, 2021, and 2022 will be 572 million yuan, 500 million yuan, and 1.5 billion yuan respectively; the adjusted net losses will be 277 million yuan, 344 million yuan, and 125 million yuan, respectively.
Baidu DCM Fosun Pharma is a shareholder
The executive directors of Yaoshibang are Zhang Buzhen and Chen Fei; the non-executive directors Lin Xinhe and Zhu Ziyang; the independent non-executive directors are Ms. Shao Rong, Sun Hanhui and Zhao Hongqiang.
Zhang Buzhen served as the vice president of SouFun.com in charge of website, technology, product and mobile terminal operation and development; he was the CTO of SouFun.com before, and he is one of the core executives who grew up with SouFun.com.
Yaoshibang completed the D round of financing of US$133 million in 2019, with a cost per share of US$4.
Yaoshibang completed the E1 round of financing of US$150 million in February 2021. The investor is Baiying Development Co., Ltd. controlled by Zhu Mengyi's Yuanzhi Group.
In April 2022, another US$85.2 million in financing was completed. Investors included Baidu, Sunshine Life Insurance Co., Ltd., GeniusII Found Limited, and Guangzhou Xinxing Huacheng Venture Capital Partnership. Among them, Baidu and Sunshine Life Insurance each invested US$30 million.
The cost per share of Pharmacist’s Series E round was $8.64.
Before the IPO, Zhang Buzhen's MIYTHoldings held 20.33% of the shares, Baiying Development Co., Ltd. held 13.29% of the shares, and Internet FundV held 12.98% of the shares.
In addition, HCapitalV holds 9.66%, Fosun Pharma holds 8.98%, DCM holds 8.65%, GeniusII holds 5.49%, and GeniusVFound holds 0.75%.
Shanghai Jixu Information Technology Partnership (Limited Partnership) holds 0.77%, Shunwei Growth III holds 3.97%, Baidu holds 2.25%, Sunshine Life Insurance holds 2.25%, and SIG Global China holds 1.73%.
Based on this calculation, when Baidu and Sunshine Life Insurance became shareholders, Yaoshibang was valued at approximately US$1.333 billion.
———————————————
Lei Di was founded by Lei Jianping, a media person. If you reprint, please indicate the source.
